Stock Ratings / Health Care / MBIO / options

CMND (48) DCOY (45) JUNS (33) SXTP (50) ⌘ Pro Terminal →

Mustang Bio Inc. (MBIO) Options Positioning, Max Pain & Unusual Sweeps

$0.39 +9.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Mustang Bio Inc. (MBIO) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $3.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MBIO)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (MBIO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for MBIO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MBIO)

✓Walkthrough of MBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.30%▼ DESCENDING CHANNEL

2026-10-30O $0.39H $0.43L $0.39C $0.39VOL 48.3K

RES: $0.46SUP: $0.31SMA50: $0.47SMA200: $0.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MBIO Butterfly Map → + Track MBIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MBIO)

Health Care Rank #565 of 1016 ⚔️ CMND vs MBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MBIO vs. CMND, DCOY, JUNS, SXTP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Mustang Bio Inc. (MBIO) ranks #565 by composite RQD confidence (43/100, grade D-) and #979 by equity capitalization ($3.0M). Within this direct 5-issuer industry benchmark cohort, MBIO leads on earnings valuation at N/A trailing P/E, while MBIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SXTP currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with MBIO at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MBIO ACTIVE Mustang Bio Inc.	D-	43/100	—	—	-35.0%	+9.00%	$3.0M	Benchmark Subject
CMND Clearmind Medicine Inc.	D	48/100	—	—	—	-3.46%	$3.0M	/cmnd-vs-mbio →
DCOY Decoy Therapeutics Inc.	D	45/100	—	—	-35.0%	+11.82%	$2.9M	/dcoy-vs-mbio →
JUNS Jupiter Neurosciences Inc.	E	33/100	—	80.6%	-35.0%	-5.20%	$3.1M	/juns-vs-mbio →
SXTP 60 Degrees Pharmaceuticals Inc.	D	50/100	—	22.3%	-35.0%	+11.87%	$3.3M	/sxtp-vs-mbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001680048

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mustang Bio Inc. (MBIO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$1.9M, operating cash flow of -$5.3M, and free cash flow of -$5.3M (+53.9% YoY). On the balance sheet, MBIO closed FY2025 with $17.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$1.9M	-$5.3M	-$5.3M	$17.6M	—
FY2024 (FY)	2024-12-31	$0	-$15.8M	-$11.4M	-$11.4M	$9.3M	—
FY2023 (FY)	2023-12-31	$0	-$51.6M	-$49.5M	-$49.5M	—	—

3. MBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Mustang Bio Inc. (NASDAQ: MBIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.39 (+9.00% 1D, market cap $3.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MBIO ranks #565 in composite RQD confidence.

How does MBIO compare to CMND and DCOY in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MBIO carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CMND (Clearmind Medicine Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $3.0M) and DCOY (Decoy Therapeutics Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.9M). Among the 5-stock peer group, MBIO leads on earnings multiple (N/A) while MBIO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MBIO?

Per MBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680048), Mustang Bio Inc. generated $0 in revenue, -$1.9M in net income, and -$5.3M in free cash flow against $17.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

MBIO last traded at $0.39 (+9.00% on volume of 44,864 shares), positioning the stock -17.02% below its 50-day simple moving average ($0.47) and -43.48% below its 200-day simple moving average ($0.69). Across its 52-week range of $0.35 to $1.45, MBIO sits at the 3.6% percentile with a 14-day RSI of 44.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.44).

MBIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is MBIO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for MBIO.

Direct Sub-Reports: MBIO RQD Cockpit MBIO 12M Forecast MBIO Earnings & Move MBIO Dividends & DRIP MBIO Insiders & 13F MBIO Whale Options MBIO Profit Sankey MBIO News & Why